Synthesis, characterization and in vitro/in vivo evaluation of novel reduction-sensitive hybrid nano-echinus-like nanomedicine
Source abstract
Abstract
To remedy the problems resulting from the usage of anti-cancer drugs in cancer chemotherapy, such as deficient drug concentration in tumour cells, low water-solubility and non-specific distribution of antitumour drugs, a kind of reduction-sensitive polymer prodrug of curcumin (Cur) containing in the nano-echinus was synthesized and designed. The nano-echinus-like nanomedicine presented synergistic effect with glycyrrhetic acid (GA) and oligomeric hyaluronic (HA) for targeting and combating HepG2 human liver cancer cell. Firstly, a kind of small molecular prodrug of Cur, dithiodipropionic acid-Cur (-SS-Cur), was chemically conjugated onto the side chain of the conjugated glycyrrhetic acid- oligomeric hyaluronic (GA-HA) to generate an amphiphilic polymeric prodrug of Cur, GA-HA-SS-Cur. The obtained GA-HA-SS-Cur prodrug and subsidiary material mPEG-DSPE could self-assemble into a sea urchin-like micelles in aqueous media and release Cur rapidly in response to glutathion (GSH). Then, Cur was loaded into the nano-echinus with a particle size of (118.1 ± 0.2 nm) and drug-loading efficiency of (8.03 ± 2.1%). The structure of GA-HA-SS-Cur was characterized by 1H-NMR in this report. The morphology of micelles was observed with a transmission electron microscope (TEM). Subsequently, the reduction-sensitivity of the nano-echinus was confirmed by the changes in in-vitro drug release after different concentrations of GSH treatment. Besides, the cellular uptake behaviour and MTT assays of the nano-echinus were investigated, suggesting that the nano-echinus was of desirable safety and could be taken into HepG2 cells in a time-dependent manner. Later, anti-tumour efficacy in vivo revealed the effective inhibition of tumour growth.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Curcumin's Biomedical Applications · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, Universities of Shandong, Yantai University, Yantai, PR China;
Department of Pharmaceutics, Yantai Yuhuangding Hospital, School of Medicine, Qingdao University, Yantai, PR China
Funding
the National Natural Science Foundation of China · Taishan Young Scholar Program
References (23)
Show source-provided references
1. 10.1080/10717544.2017.140656110.1080/10717544.2017.1406561 ↗
2. 10.1080/10717544.2017.127923810.1080/10717544.2017.1279238 ↗
3. 10.1021/acs.molpharmaceut.5b0067710.1021/acs.molpharmaceut.5b00677 ↗
4. 10.18632/oncotarget.608410.18632/oncotarget.6084 ↗
5. 10.1016/j.bmc.2018.02.02110.1016/j.bmc.2018.02.021 ↗
6. 10.1016/j.bmc.2017.08.00210.1016/j.bmc.2017.08.002 ↗
7. 10.1016/j.bmc.2007.05.05710.1016/j.bmc.2007.05.057 ↗
8. Satomi Y · Anticancer Res · 2005 · 25 · 4043
9. 10.1039/C6RA01580H10.1039/C6RA01580H ↗
10. 10.3390/md1109351710.3390/md11093517 ↗
11. 10.1007/s00396-014-3429-z10.1007/s00396-014-3429-z ↗
12. 10.1016/j.msec.2017.02.03010.1016/j.msec.2017.02.030 ↗
13. 10.1016/j.actbio.2017.12.02810.1016/j.actbio.2017.12.028 ↗
14. 10.1016/j.carbpol.2017.03.03110.1016/j.carbpol.2017.03.031 ↗
15. 10.1002/adma.20140070310.1002/adma.201400703 ↗
16. 10.1039/C7CS00492C10.1039/C7CS00492C ↗
17. XiaHou F · Acta Biomater · 2017 · 68 · 308
18. 10.1016/j.msec.2017.03.12410.1016/j.msec.2017.03.124 ↗
19. 10.1080/21691401.2017.141639010.1080/21691401.2017.1416390 ↗
20. 10.1016/j.ijbiomac.2017.12.06910.1016/j.ijbiomac.2017.12.069 ↗
21. 10.1016/j.carbpol.2017.05.03410.1016/j.carbpol.2017.05.034 ↗
22. 10.1016/j.ijbiomac.2017.11.00210.1016/j.ijbiomac.2017.11.002 ↗
23. 10.1002/mabi.20150031710.1002/mabi.201500317 ↗